These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1393 related articles for article (PubMed ID: 17062708)

  • 1. Clinical features of metastatic bone disease and risk of skeletal morbidity.
    Coleman RE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6243s-6249s. PubMed ID: 17062708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
    Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
    J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal complications of malignancy.
    Coleman RE
    Cancer; 1997 Oct; 80(8 Suppl):1588-94. PubMed ID: 9362426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical features of pathologically confirmed metastatic bone tumors--a report of 390 cases].
    Xu DL; Zhang XT; Wang GH; Li FB; Hu JY
    Ai Zheng; 2005 Nov; 24(11):1404-7. PubMed ID: 16552972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
    Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
    Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metastases from advanced cancers: clinical implications and treatment options.
    Fitch M; Maxwell C; Ryan C; Löthman H; Drudge-Coates L; Costa L
    Clin J Oncol Nurs; 2009 Dec; 13(6):701-10. PubMed ID: 19948468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic skeletal disease distal to the elbow and knee.
    Leeson MC; Makley JT; Carter JR
    Clin Orthop Relat Res; 1986 May; (206):94-9. PubMed ID: 3708998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?
    Tankó LB; Karsdal MA; Christiansen C; Leeming DJ
    Cancer Metastasis Rev; 2006 Dec; 25(4):659-68. PubMed ID: 17160557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone metastases, general and clinical issues.
    Greco C; Forte L; Erba P; Mariani G
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):337-52. PubMed ID: 21738111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy in the management of bone pain.
    Hoskin PJ
    Clin Orthop Relat Res; 1995 Mar; (312):105-19. PubMed ID: 7543390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clodronate in the prevention and treatment of skeletal metastasis.
    Gulley J; Dahut WL
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):221-30. PubMed ID: 15877520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.
    Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M
    J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
    Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Lung Cancer; 2009 Aug; 65(2):219-22. PubMed ID: 19081161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multistate analysis of skeletal events in patients with bone metastases.
    Cook RJ; Major P
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6264s-6269s. PubMed ID: 17062711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the treatment of bone metastases.
    Reich CD
    Clin J Oncol Nurs; 2003; 7(6):641-6. PubMed ID: 14705479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem.
    Pluijm G; Löwik C; Papapoulos S
    Cancer Treat Rev; 2000 Feb; 26(1):11-27. PubMed ID: 10660489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone metastases: Part I--Pathophysiology.
    Fisher G; Mayer DK; Struthers C
    Clin J Oncol Nurs; 1997 Apr; 1(2):29-35. PubMed ID: 9410649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of therapeutic agents to bone to treat metastatic cancer.
    Bagi CM
    Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.